Thymus Lymphoma — Trials

Thymus Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

127 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 58
Recruiting: 33
Ph III recruiting: 0
Growth YoY: —
Industry share: 24%
Top sponsor: University of Washington
Termination share: 30.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (13)

clinicaltrialsPublishedShowing 51–71 of 71 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06834373	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy	recruiting	Phase 2	41	Mayo ClinicOTHER	1	Jan 28, 2026	clinicaltrials
NCT01599559	Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma	active not recruiting	N/A	540	International Extranodal Lymphoma Study Group (IELSG)OTHER